Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Leber Hereditary Optic Neuropathy
Conditions
Leber Hereditary Optic Neuropathy
Trial Timeline
Mar 12, 2018 → Jul 23, 2024
NCT ID
NCT03293524About Placebo
Placebo is a phase 3 stage product being developed by GenSight Biologics for Leber Hereditary Optic Neuropathy. The current trial status is completed. This product is registered under clinical trial identifier NCT03293524. Target conditions include Leber Hereditary Optic Neuropathy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03293524 | Phase 3 | Completed |
Competing Products
12 competing products in Leber Hereditary Optic Neuropathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| EDIT-101 | Editas Medicine | Phase 1/2 | 33 |
| AAV RPE65 | MeiraGTx | Phase 1/2 | 33 |
| AAV OPTIRPE65 | MeiraGTx | Pre-clinical | 15 |
| Idebenone + Placebo | Santhera Pharmaceuticals | Phase 2 | 44 |
| Idebenone | Santhera Pharmaceuticals | Approved | 77 |
| Idebenone 150 MG Oral Tablet | Santhera Pharmaceuticals | Pre-clinical | 15 |
| Idebenone | Santhera Pharmaceuticals | Pre-clinical | 15 |
| sepofarsen | ProQR | Phase 2/3 | 57 |
| sepofarsen | ProQR | Phase 2/3 | 57 |
| Idebenone + Placebo | Santhera Pharmaceuticals | Phase 3 | 69 |
| GS010 | GenSight Biologics | Phase 3 | 69 |
| GS010 | GenSight Biologics | Phase 3 | 69 |